Soligenix (SNGX) Stock Price & Analysis Today

SNGX

(NASDAQ)

Soligenix, Inc.

$0.38-- (--)

Loading... - Market loading

Overview Financials Forecast Statistics Dividends Historical Profile

Soligenix Stock Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fundamental metrics, valuation ratios, and profitability indicators

Day's Range$0.34 - $0.41

52-Week High$6.23

52-Week Low$0.28

Open$0.38

Volume4.29M

Average Volume (3M)1.33M

Market Cap1.87M

Shares Outstanding5.19M

Price to Book (P/B)0.35

EV/EBITDA0.46

50-Day MA$1.02

200-Day MA$1.60

52-Week Change-85.67%

Annual Dividend$0.00

Dividend Yield0.00%

Day's Range$0.34 - $0.41

52-Week High$6.23

52-Week Low$0.28

Open$0.38

Volume4.29M

Average Volume (3M)1.33M

Market Cap1.87M

Shares Outstanding5.19M

Price to Book (P/B)0.35

EV/EBITDA0.46

50-Day MA$1.02

200-Day MA$1.60

52-Week Change-85.67%

Annual Dividend$0.00

Dividend Yield0.00%

About Soligenix

Company overview, fundamentals, and corporate profile

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States.It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet’s disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis.Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola.The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009.Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Frequently Asked Questions About Soligenix

What is the current stock price for SNGX?

As of the latest trading session, SNGX stock trades at $0.41. The 52-week range is $0.28–$6.23, with a day range of $0.34–$0.41.

What is the P/E ratio for SNGX?

The P/E ratio (Price-to-Earnings) for SNGX is shown in the Key Statistics section. This valuation metric helps compare Soligenix, Inc. to industry peers.

Does SNGX pay dividends?

Soligenix does not currently pay a regular dividend. The company reinvests earnings into growth and operations. Check the Dividends tab for historical dividend information.

What do analysts recommend for SNGX?

Analyst ratings and recommendations for SNGX are displayed in the Analyst Consensus section, including buy/hold/sell distribution and 12-month price targets.

What is the market cap of SNGX?

Soligenix's market capitalization is $2.1M, classifying it as a micro-cap company. Soligenix operates in the Healthcare sector within the Biotechnology industry.

Soligenix (SNGX) Stock Price & Financial Analysis

Soligenix Stock Price Chart

Price Chart

Financial Metrics & Key Statistics

Frequently Asked Questions About Soligenix